DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch
biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss
Exchange: CRX), today announced that GlaxoSmithKline (GSK) signed a license
agreement allowing GSK to research a recombinant protein on the PER.C6®
platform. Financial terms of the agreement were not disclosed.
DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch
biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss
Exchange: CRX), today announced that CSL Limited, a global biopharmaceutical
company headquartered in Melbourne, Australia, signed a license agreement
allowing CSL to develop protein therapeutics for multiple undisclosed disease
targets on the PER.C6® platform. Under the terms of the agreement, CSL is
responsible for the development of protein and antibody products resulting
from this alliance. Financial terms of the agreement were not disclosed.
DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch
biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX), today announced that Hungary-based Gedeon Richter Plc. signed a
commercial license agreement allowing Gedeon Richter to develop and produce
certain biopharmaceuticals on the PER.C6® platform.
DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX)
announced today that the high-titer fed-batch process developed at the
PERCIVIA PER.C6® Development Center, their joint venture in Cambridge, USA was
recently scaled up to 250 liters by DSM Biologics scientists at their GMP
facility in Groningen, The Netherlands. They successfully achieved 8 grams per
liter for an IgG expressed by PER.C6® cells using chemically defined cell
culture medium in a SUB (single-use bioreactor).
DSM Biologics and MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard
Segment, TecDAX) today announced the signing of a Biopharmaceutical
Manufacturing Agreement covering process development and cGMP manufacturing of
MOR202.
DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX)
announced today that they have entered into an agreement with Avid
Bioservices, Inc. of Tustin, California to join their Vendor Network. Under
the terms of the agreement, Avid will be a pre-approved contract manufacturer
(CMO) for licensees of the PER.C6® cell line located in the western U.S. Avid
is the first U.S.-based contract manufacturer to be awarded this status.
DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX)
today announce another breakthrough in the production of IgG antibodies using
PER.C6® technology. By employing the PER.C6® human cell line and proprietary
XD™ technology, a record yield of over 27 grams per liter has been achieved.
In March 2008 a yield of 15 grams per liter was reported.
DSM Biologics, a business unit of DSM Pharmaceutical Products, and Upfront
Chromatography A/S, a leading developer of customized industrial-scale
separation services, today announced the collaboration between the two
companies to optimize Upfront’s new, fully disposable chromatography system
for use with DSM's proprietary manufacturing technology.
DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch
biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) today announced that German-based MorphoSys AG has decided to extend the
PER.C6® technology licensing agreement entered in September 2004, exercising
an option for clinical and commercial production of antibodies.
DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch
biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange:
CRX) announced today that another important milestone has been achieved with
the PER.C6® technology platform for the production of monoclonal antibodies
and recombinant proteins.
DSM Pharmaceuticals, Inc. a business unit of DSM Pharmaceutical Products has
announced today Mr. Hans Engels has been appointed to the position of
President and Business Unit Director of DSM Pharmaceuticals, Inc.
DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, has
successfully launched PharmaPLE™ during the Informex tradeshow in New Orleans.
PharmaPLE™ is a recombinant pig liver esterase, which has been scaled and
applied successfully in the synthesis of pharma intermediates
DSM Pharmaceuticals, Inc. a business unit of DSM Pharmaceutical Products and
APT Pharmaceuticals, Inc. announced today they have signed a manufacturing
agreement.
DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products and DSM
Anti-Infectives are pleased to announce today the DSM team has been awarded
the Gold DSM Innovation Award 2007.
DSM recently celebrated being awarded the North Carolina International
Community and Economic Development Award, an award given by the N.C.
Department of Commerce in recognition of the important civic and philanthropic
contributions made by foreign-owned businesses.
DSM Pharmaceuticals Inc. and the Food and Drug Administration (FDA) have
recently signed an agreement to collaborate on a project involving Statistical
Quality by Design Methodology during Pharmaceutical Manufacturing.
